Alpha Tau Medical Ltd. (NASDAQ:DRTS) to Post Q2 2025 Earnings of ($0.13) Per Share, HC Wainwright Forecasts

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Alpha Tau Medical in a research report issued on Wednesday, May 22nd. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of ($0.13) for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.51) per share.

Alpha Tau Medical Stock Performance

Alpha Tau Medical stock opened at $2.71 on Thursday. The business has a 50 day simple moving average of $2.72 and a 200 day simple moving average of $2.94. The company has a debt-to-equity ratio of 0.07, a quick ratio of 12.07 and a current ratio of 11.60. Alpha Tau Medical has a one year low of $2.15 and a one year high of $4.80.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings data on Monday, May 20th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02.

Hedge Funds Weigh In On Alpha Tau Medical

Several institutional investors have recently bought and sold shares of DRTS. USAdvisors Wealth Management LLC bought a new position in Alpha Tau Medical in the 1st quarter valued at $30,000. Telemus Capital LLC acquired a new stake in shares of Alpha Tau Medical in the 4th quarter valued at $89,000. Satovsky Asset Management LLC acquired a new stake in shares of Alpha Tau Medical in the 4th quarter valued at $176,000. Private Advisor Group LLC acquired a new stake in shares of Alpha Tau Medical in the 4th quarter valued at $176,000. Finally, Levin Capital Strategies L.P. increased its stake in shares of Alpha Tau Medical by 288.4% in the 4th quarter. Levin Capital Strategies L.P. now owns 330,123 shares of the company’s stock valued at $994,000 after buying an additional 245,123 shares during the period. Institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.